



Anti-Human IgG(H+L), AlpSdAbs[®] VHH (HRP)

Summary

Code	023-106-005
Immunogen	Recombinant human IgG
Host	Alpaca pacous
Isotype	VHH domain of alpaca IgG2b/2c
Conjugate	HRP
Specificity	Human IgG(H+L)
Cross-Reactivity	Recognizes human IgG(H+L) specifically, and reacts with cynomolgus IgG. No Cross-reactivity to rabbit , mouse, rat, goat IgG
Purity	Recombinant Expression and Affinity purified
Concentration	1mg/ml
Formation	Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% glycerol
Storage	Store at -20 °C(Avoid freeze / thaw cycles), protect from light

Description

Anti-Human IgG(H+L), AlpSdAbs[®] VHH(HRP) is designed for detecting human IgG(H+L) specifically. Anti-Human IgG(H+L), AlpSdAbs[®] VHH(HRP) is based on recombinant single domain antibodies to human IgG(H+L) coupled to HRP. Based on immunoelectrophoresis and/or ELISA, Anti-Human IgG(H+L), AlpSdAbs[®] VHH(HRP) reacts with the human IgG(H+L) specifically.

Background

VHH are single-domain antibodies derived from the variable regions of heavy chain of Camelidae immunoglobulin. The size of VHH is extremely small compared to other forms of antibody fragment, which significantly increase the permeability of VHH. Thus VHH is considered of great value for research, diagnostics and therapeutics.

Benefits

High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production

Application notes

ELISA	1:10,000-1:50,000
WB	1:10,000-1:50,000

Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.

This product is for research use only and is not approved for use in humans or in clinical